07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Best of both worlds

Natural killer (NK) cells aren't the only new class of immune cells attracting attention for immuno-oncology. A group from Baylor College of Medicine has found a subset of natural killer T (NKT) cells, a cell...
08:00 , Feb 14, 2013 |  BC Innovations  |  Cover Story

Cancer target selection pressure

Cancer drug discovery does not suffer from a dearth of targets-instead it is in need of a way to prioritize target selection. Now, a team from The Institute of Cancer Research has created a computational...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Affitech, General Electric deal

Affitech granted General Electric's GE Healthcare Life Sciences unit exclusive, worldwide rights to market Affitech's recombinant Protein L products. GE said it will develop products used to purify protein-based therapies. Affitech is eligible for royalties....
08:00 , Dec 12, 2005 |  BioCentury  |  Strategy

Find a hole and fill it

Improving the creation and screening of phage-based antibody libraries can be a risky task, as Cambridge Antibody Technology Group plc holds a key patent on the technology. However, Affitech AS believes it has found a...
08:00 , Dec 12, 2005 |  BioCentury  |  Strategy

Affitech deals

Affitech deals Since 2001, Affitech has closed four technology licensing deals as well as seven therapeutic collaborations in cancer, infectious and immune diseases. (A) Not active due to Axaron's change of focus Partner Date Focus...
07:00 , Oct 5, 1998 |  BC Week In Review  |  Company News

Actigen Ltd. sales and marketing update

Actigen launched its Protein LA hybrid affinity protein product, which combines the immunoglobulin binding domains of both Protein L and Protein A, for antibody detection and purification. Actigen Ltd., Cambridge, U.K.   Business: Supply/Service  ...
07:00 , Sep 21, 1998 |  BC Week In Review  |  Company News

Actigen Ltd., Actinova Ltd., CBD Technologies Inc. deal

Actinova will supply its Protein L gene to CBD Technologies, which will prepare, express and test a cellulose-binding domain-Protein L fusion protein. The fusion protein will be used to develop a matrix for large-scale antibody...
07:00 , Jun 1, 1998 |  BC Week In Review  |  Company News

Actinova Ltd., Invitrogen deal

Invitrogen acquired the rights to vectors it manufactures that incorporate the coding sequence for one or more Ig binding domains of Actinova's Protein L, a bacterial immunoglobulin-binding protein. Invitrogen also received a non-exclusive worldwide license...
08:00 , Mar 2, 1998 |  BC Week In Review  |  Company News

Actinova Ltd., Repligen deal

RGEN granted Actinova an exclusive license to develop Protein LA, an affinity protein comprising a functional Protein A molecule genetically fused to Actinova's recombinant Protein L, for the European research market. RGEN also signed a...
08:00 , Nov 3, 1997 |  BC Week In Review  |  Company News

Actinova Ltd., MBI Fermentas deal

Actinova and MBI signed a North American distribution and development agreement covering Actinova's protein L affinity protein for bioseparations. MBI will use the protein to extend its range of separations products. Actinova Ltd., Cambridge, U.K....